1. Introduction {#sec1}
===============

*Hafnia alvei* is a facultative anaerobic gram-negative bacterium belonging to the Enterobacteriaceae family. Although this genus was first described in 1954, very little is known about its role in human infectious diseases.*H. alvei* can be recovered from soil, water, and many animal species, especially mammals, where it colonises primarily the gastrointestinal tract \[[@B1]\]. In humans,*H. alvei* seems to be a member of the normal gut microbiome as a nonpathogenic inhabitant, although some studies conclude that these bacteria cause significant clinical gastroenteritis \[[@B1], [@B2]\], especially in children \[[@B3]\], but also in adult patients suffering from chronic disease or after previous antibiotic therapy \[[@B4]\]. It would appear that*H. alvei* is a microorganism with limited pathogenicity in humans that may cause clinically significant infections only in immunocompromised individuals, for example, those with malignancy or after organ transplantation \[[@B6], [@B5]\]. We here describe a renal transplant recipient who suffered from*H. alvei* urosepsis.

2. Case Report {#sec2}
==============

The 56-year-old woman developed end-stage renal disease due to IgA nephropathy. In August 2012 she underwent preemptive kidney transplantation, receiving a kidney allograft from her husband. Her posttransplant course was stable with a serum creatinine of 0.90 mg/dL (eGFR 75 mL/min), and medical therapy consisted of tacrolimus (blood levels between 5 and 7 ng/mL), azathioprine, simvastatin, and pantoprazole.

Two days before admission in November 2014 she experienced headache, shivering, nausea, repeated vomiting, and diarrhea. At admission she had fever of 38°C. Blood tests showed a mild leukocytosis of 10.5 G/L (neutrophils 84%) and CRP of 20 mg/dL and her serum creatinine had increased to 1.30 mg/dL. An ultrasound of the transplant was unremarkable. The urinary sediment contained multiple leukocytes and bacteria. A diagnosis of transplant pyelonephritis was made and cefepime 2 g b.i.d. was commenced. Cultures taken from urine and blood samples taken on admission grew*H. alvei* identified by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI TOF) (MALDI Biotyper©Microflex LT, Bruker Daltonics, Bremen, Germany). No coinfection with other bacteria could be identified. The results of antimicrobial susceptibility testing using the VITEK 2 system (bioMerieux) are shown in [Table 1](#tab1){ref-type="table"}.

Under antibiotic therapy the patient\'s symptoms and fever subsided and serum creatinine decreased to 0.90 mg/dL within two days. After five days antibiotic therapy was switched to ciprofloxacin 500 mg b.i.d. and the patient was discharged. At an outpatient control one week later she was in excellent clinical condition, laboratory parameters had normalised, and antibiotic therapy could be discontinued.

3. Discussion {#sec3}
=============

Although relatively little is known about the role of*H. alvei* in human clinical infection, some common themes do emerge. First of all,*H. alvei* is rarely found in human specimens, mostly from the respiratory and gastrointestinal tract, urine, blood, wounds, and abscesses \[[@B7], [@B8]\]. In the majority of these cases, however, the bacterium does not seem to be related to the clinical infection. For example, whether*H. alvei* can cause acute gastroenteritis is still a matter of debate \[[@B1], [@B2]\]. Günthard and Pennekamp found*H. alvei* in 80 specimens but considered it to be pathogenetic in only three patients (two with septicemia and one with peritonitis). Secondly, most patients seem to have underlying conditions which predispose them to infection. For example, in the series studied by Günthard and Pennekamp, 93% of the patients had an underlying disease, mainly malignancy. Thirdly, in most cases infection with*H. alvei* is nosocomial. Rodríguez-Guardado in a collective of 36 patients with extraintestinal infection due to*H. alvei* over an eleven-year period found that 25 were nosocomial and eleven community-acquired \[[@B8]\]. In addition to underlying comorbidities, 76% of patients had other predisposing risk factors such as surgery, intravenous catheter insertion, or antibiotic therapy \[[@B7]--[@B9]\]. And lastly, in most specimens a coinfection with other, more pathogenic bacteria such as*Staphylococcus aureus* was seen \[[@B8]\].

At our institution 40*H. alvei* isolates have been detected over the last ten years. Most positive specimens were obtained from respiratory tract secretions in intubated patients or from infections after abdominal surgery. Only three positive blood cultures were found and two of these patients had an underlying malignancy.

Several cases of*H. alvei* infection have been described in stem cell and particularly solid organ transplant recipients. Intestinal colonization and possible infection with*H. alvei* have been reported in a 9-year-old girl after hematopoietic stem cell transplantation for Fanconi\'s anemia. Two patients, one 61-year-old woman and a 2-year-old boy, developed hepatic abscess after liver transplantation. The first patient had coinfection with*Enterococcus faecalis* and*Candida albicans* and the second with*Enterococcus faecalis*. Immunosuppressive and antimicrobial treatment are specified in [Table 2](#tab2){ref-type="table"}. Günthard and Pennekamp reported a positive specimen in a lung transplant patient, but without further details.

Clinically significant*H. alvei* infection has also been reported in two renal transplant recipients.

The first patient was a 69-year-old female who developed sepsis and pneumonia nine years after renal transplantation. Basal immunosuppression consisted of cyclosporine, azathioprine, and steroids. The patient also suffered from hepatitis C infection. She developed hypotension, oliguria, and coagulopathy and recovered after hemodynamic support and antibiotic therapy with imipenem and clarithromycin.

The second case was a 45-year-old female suffering from ESRD due to diabetic nephropathy. Her course after transplantation was complicated by acute humoral rejection and chronic rejection.*H. alvei* pyelonephritis developed after ureteral stent implantation for hydroureteronephrosis. The patient recovered after treatment with ceftriaxone, cefixime, and removal of the stent.

Our case is similar to these two reports. We also were unable to identify the source of the infection. Certain foods, especially meat and fish, may harbour*H. alvei* in large amounts \[[@B10]\]. As*H. alvei* is part of the normal gut microbiota, we believe that the gastrointestinal tract, as common in urinary tract infections, was the most likely source of infection. None of these kidney transplant patients had a coinfection with other more aggressive bacteria. The two other patients, however, had additional comorbidities, namely, diabetes in one and hepatitis C infection in the other patient. In one patient*H. alvei* infection developed after an invasive procedure. The other two patients had triple immunosuppressive therapy including prednisolone, whereas our patient only had double therapy without steroids. All three patients ultimately recovered after appropriate antibiotic therapy.

In conclusion,*H. alvei* can cause severe infection such as urosepsis, pyelonephritis, and pneumonia in renal allograft recipients. Antimicrobial therapy with carbapenems, quinolones, or fourth-generation cephalosporins is necessary to cure the infection.
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###### 

Susceptibility testing of *H. alvei* recovered from the blood culture.

  Sensitive                       Resistant
  ------------------------------- -----------------------------
  Cefotaxime/ceftazidime          Ampicillin
  Cefepime                        Amoxicillin/clavulanic acid
  Ertapenem/meropenem             Piperacillin/tazobactam
  Gentamicin                      Fosfomycin
  Ciprofloxacin                    
  Trimethoprim/sulfamethoxazole    

###### 

*H. alvei* infections in transplant recipients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                      Age   Sex   Underlying disease                             Type of transplant      Immunosuppression                    Risk factors                                   Antibiotic treatment                           Outcome
  --------------------------- ----- ----- ---------------------------------------------- ----------------------- ------------------------------------ ---------------------------------------------- ---------------------------------------------- ---------
  Savini et al. \[[@B6]\]     9     F     Fanconi\'s anaemia                             Allogeneic stem cells   Cyclosporine steroids\               Graft versus host disease                      Ceftazidime, amikacin, and teicoplanin         Cured
                                                                                                                 antilymphocyte antibody                                                                                                            

                                                                                                                                                                                                                                                    

  Barry et al. \[[@B5]\]      61    F     Primary biliary cirrhosis                      Liver                   Unknown                              Recurrent rejection, additional infection      Piperacillin/\                                 Died
                                                                                                                                                                                                     tazobactam, gentamicin, and amphotericin B     

                                                                                                                                                                                                                                                    

  Barry et al. \[[@B5]\]      2     M     Autoimmune hepatitis                           Liver                   Unknown                              Previous high dose steroids and OKT3 therapy   Trimethoprim/\                                 Cured
                                                                                                                                                                                                     sulfamethoxazole, gentamicin, and ampicillin   

                                                                                                                                                                                                                                                    

  Cardile et al. \[[@B11]\]   45    F     Diabetic nephropathy                           Kidney                  Tacrolimus\                          Diabetes\                                      Cefixime                                       Cured
                                                                                                                 MMF\                                 ureteral stent                                                                                
                                                                                                                 prednisone                                                                                                                         

                                                                                                                                                                                                                                                    

  Benito et al. \[[@B12]\]    69    F     Autosomal dominant polycystic kidney disease   Kidney                  Cyclosporine azathioprine steroids   Hepatitis C                                    Imipenem and clarithromycin                    Cured

                                                                                                                                                                                                                                                    

  This study                  56    F     IgA nephropathy                                Kidney                  Tacrolimus azathioprine              None                                           Cefepime and ciprofloxacin                     Cured
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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